<DOC>
	<DOCNO>NCT02443012</DOCNO>
	<brief_summary>Diabetic macular edema ( DME ) major cause visual loss patient diabetes mellitus . The standard treatment focal/grid laser therapy . Topical nepafenac use adjunct therapy treatment DME . The aim study compare difference best correct visual acuity ( BCVA ) central macular thickness ( CMT ) 3 month post treatment combination therapy laser topical nepafenac laser monotherapy patient DME .</brief_summary>
	<brief_title>Topical Nepafenac Supplement Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetes mellitus systemic complication enormous health treat world population today . In US , ophthalmic related complication estimate cause 4.2 million ( 28.5 % ) people 2005 till 2008 suffer blindness . One common cause visual acuity loss patient diabetes mellitus diabetic macular edema ( DME ) . The gold standard treatment clinically significant macular edema ( CSME ) , form DME , focal grid laser show Early Treatment Diabetic Retinopathy Study . The development newer drug anti vascular endothelial growth factor anti ( VEGFs ) , alternative laser treatment , become topic interest recent year . Other alternative treatment DME steroid triamcinolone injection dexamethasone injection . However , anti VEGFs steroid expensive readily available centre . Both type medication require repeat treatment route administration intravitreal also pose risk endophthalmitis , lens injury , retinal detachment , vitreous hemorrhage , increase intraocular pressure cataract . The pathophysiology DME fully understand yet . It suggest likely chronic low-grade inflammation . Through theory , topical non-steroidal anti-inflammatory drug ( NSAIDs ) use treat DME . The investigator postulate addition topical NSAIDs patient receive standard treatment laser therapy may help improve outcome patient DME . It advantage needle involve , convenient , easy use minimal side effect . The aim study evaluate outcome visual acuity macular thickness 3 month post treatment laser monotherapy combination laser topical nepafenac DME .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Type 2 Diabetes Mellitus CSME Aged 18 70 year old Clear medium ( Able perform OCT ) HbA1c le 12 % 3 month CSME severe NonProliferative Diabetic Retinopathy ( NPDR ) Proliferative Diabetic Retinopathy ( PDR ) Previous laser treatment Previous ocular injury surgery History take topical systemic anti inflammatory agent Allergic NSAIDs Other ocular pathology ( ARMD , Glaucoma , IPCV ) High myope</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Nepafenac</keyword>
	<keyword>Laser therapy</keyword>
	<keyword>Clinically significant macular edema</keyword>
	<keyword>Adjunct Treatment</keyword>
	<keyword>Topical Nepafenac</keyword>
</DOC>